Huahai Pharmaceutical's Subsidiary Launches Phase III Clinical Trial of HB0025 Injection for Endometrial Cancer

Gelonge News, March 18 | Huahai Pharmaceutical announced that its subsidiary, Shanghai Huaota Biopharmaceutical Co., Ltd., following communication with the Center for Drug Evaluation of the National Medical Products Administration at the end of Phase II clinical trials and prior to the start of Phase III clinical trials, has officially launched the Phase III clinical trial of HB0025 injection for endometrial cancer. HB0025 is an innovative anti-PD-L1/VEGF bispecific fusion protein independently developed by Huaota, targeting both the tumor immune escape pathway PD-L1 and the tumor angiogenesis pathway VEGF. The drug design achieves high-affinity binding to both targets, synergistically regulating the tumor immune microenvironment and angiogenesis, featuring a dual anti-tumor mechanism of "immune enhancement + anti-angiogenesis."